Table 3 Univariate analysis of the association of treatment system – related characteristics with an unfavourable outcome in 629 cases treated for at least 24 hours

Specialty responsible for starting treatment¹

pulmonary

579

90

1

76

1

internal medicine

34

11

2.52 (1.17–5.45)

0.018

3

0.82 (0.24–2.81)

0.75

general medicine

6

2

3.06 (0.50–18.58)

0.22

61

1.81 (0.18–17.65)

0.61

other

9

4

3.67 (0.97–13.34)

0.056

0

-

-

Specialty responsible for ending treatment²

pulmonary

531

61

1

67

1

internal medicine

28

17

18.72 (7.10–49.23)

<0.001

5

5.01 (1.49–16.89)

0.009

general medicine

47

22

6.92 (3.59–13.34)

<0.001

4

1.15 (0.38–3.44)

0.81

other

15

6

4.96 (1.66–14.77)

0.004

1

0.75 (0.093–6.11)

0.79

Change of specialty responsible for treatment²

no

530

66

1

71

1

yes

91

40

5.29 (3.21–8.72)

<0.001

6

0.74 (0.30–1.79)

0.68

Number of cases per year for unit giving initial treatment

1 – 4

36

6

0.91 (0.355–2.34)

0.85

5

1.19 (0.59–2.40)

0.64

5 – 10

30

46

1.20 (0.46–3.16)

0.71

5

0.67 (0.32–1.43)

0.30

11 – 29

286

50

0.84 (0.54–1.32)

0.46

33

1.16 (0.59–2.28)

0.67

30 -

277

50

1

37

1

Number of cases per year for unit responsible for ending treatment

1 – 4

93

33

3.27 (1.83–5.84)

<0.001

15

1.79 (0.89–3.63)

0.11

5 – 10

38

5

0.80 (0.287–2.207)

0.67

5

0.96 (0.34–2.69)

0.39

11 – 29

278

35

0.74 (0.44–1.23)

0.24

31

0.79 (0.46–1.36)

0.39

30 -

220

35

1

29

1

Treatment group

standard treatment A

309

64

1

25

1

standard treatment B

54

7

0.86 (0.36–2.06)

0.73

19

5.97 (2.92–12.20)

<0.001

standard treatment C

33

1

0.13 (0.018–0.99)

0.05

6

2.03 (0.76–5.41)

0.16

standard treatment D

155

24

0.72 (0.43–1.21)

0.28

16

1.22 (0.63–2.38)

0.55

other combination

9

4

0.56 (0.25–1.25)

0.16

2

5.87 (0.94–36.81)

0.06

ineffective

69

8

4.58 (1.00–21.01)

0.05

12

2.16 (1.01–4.58)

0.05

Treatment combination

standard (A – D)

548

97

1

66

1

non-standard

81

11

0.78 (0.38–1.55)

0.62

14

1.46 (0.77–2.77)

0.28

Change in treatment group

no

433

91

1

41

1

yes

196

17

0.40 (0.23–0.70)

0.001

39

2.05 (1.26–3.31)

0.004

Pause of treatment²

no

464

88

1

37

1

yes

157

16

0.64 (0.36–1.13)

0.14

42

3.97 (2.42–6.562)

<0.001

Pause during intensive phase²

no

483

91

1

44

1

yes

134

13

0.58 (0.31–1.082)

0.09

35

3.22 (1.95–5.32)

<0.001

Pause during intensive phase, due to side effect

no

523

97

1

56

1

yes

106

11

0.59 (0.30–1.16)

0.13

24

2.23 (1.30–3.84)

0.005

Pause during continuation phase

no

481

51

1

50

1

yes

70

8

1.49 (0.66–3.36)

0.35

22

4.18 (2.299–7.601)

<0.001

NA (other + ineffective)

78